Abstract: A polyplex of a double stranded RNA (dsRNA) and a polymeric conjugate consists of a linear polyethyleneimine (PEI) covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety is conjugated via a linker to a targeting moiety capable of binding to a cancer antigen. Exemplary cancer antigens include epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and prostate surface membrane antigen (PSMA).

Abstract: The present invention provides therapeutic products with decreased fibrinolytic activity of t-PA-deficient and/or plasminogen-deficient blood products, as well as compositions, kits and methods using the same in treating bleeding associated with hereditary or acquired bleeding disorders. The invention further provides extracorporeal apparatus for blood or blood products Plasmapheresis aimed to prevent or treat bleeding disorders.

Abstract: Provided by the disclosure are methods for modulating differentiation of regulatory T cells (e.g., CD4+ or CD8+ regulatory T cells). In some embodiments, methods include contacting regulatory T cells with an agent that decreases Helios activity and/or Helios expression.

Abstract: The present invention relates to T cells, in particular a non-activated T cell, comprising an exogenous nucleic acid encoding a T cell Receptor (TCR) specific for a virus. An embodiment of the invention is directed to a non-activated (resting) T cell expressing Hepatitis B virus (HBV) envelope s183-191 TCR capable of inhibiting viral replication and which shows reduced expression of perforins and/or granzymes in response to stimulation as compared to an activated T cell expressing the said TCR. Also encompassed are methods for producing such cells, compositions, pharmaceutical compositions and kits comprising such cells and medical uses thereof.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.

Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.

Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The disclosure provides immunogenic cells expressing LMP1, and use thereof in activating T cells and treating cancer. Also provided are methods of producing the immunogenic cells.

Abstract: The invention relates to chimeric antigen receptor (CAR) specific to p80 and CD146, vectors encoding the same, and recombinant T cells comprising the p80 or CD146 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a p80 or CD146 binding domain.

Abstract: The purpose of the present invention is to provide a novel medicinal use in regeneration medicine, said medicinal use comprising using pluripotent stem cells (Muse cells). Provided is a cell preparation for treating skin ulcer, said cell preparation comprising SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue of a living organism or cultured mesenchymal cells. The cell preparation according to the present invention is based on such mechanism of skin tissue regeneration that, when the Muse cells are administered to a skin ulcer site of a subject suffering from the aforesaid disease, the Muse cells differentiate into skin-constituting cells.

Abstract: This disclosure relates to methods and compositions for modulating (e.g., increasing) Atoh1 activity (e.g., biological activity) and/or expression (e.g., transcription and/or translation) in vivo and/or in vitro, e.g., in a biological cell and/or in a subject. The methods and compositions described herein can be used in the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression in a biological cell.

Abstract: Provided herein are exosomal compositions and exsosomal IncRNA compositions and formulations thereof. Also provided herein are methods of treating a wound in a subject in need thereof that can contain the step of administering an exosomal composition and/or exsosomal IncRNA compositions or formulation thereof to a wound in a subject in need thereof.

Abstract: Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.

Abstract: A method of preventing or treating eosinophilic esophagitis (EoE) comprising administering a composition comprising ascr#7 is described.

Abstract: The present invention relates to a combination of a blood preparation and a helminthic preparation for use as a medicament, wherein the blood preparation is preparable by a production method comprising the following steps: providing a blood sample collected from an organism and a vessel or container, contacting said blood sample with said vessel or a container, and incubating said blood sample in said vessel or container, wherein said blood sample is (1) a whole blood sample or (2) a whole blood sample from which certain or all cells have been depleted. Moreover, the present invention relates to the non-therapeutic use of a blood preparation in combination with a helminthic preparation, wherein the helminthic preparation comprises helminths which are incapable of reproducing in the organism and/or which do not infect the organism and particularly do not chronically infect the organism, and wherein the blood preparation is preparable by a production method as described above.

Abstract: Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.

Abstract: Methods and compositions for populating the gastrointestinal tract of a subject are described. Methods include administering to a subject a therapeutic composition comprising a purified population of spore-forming bacteria produced by providing a fecal material and subjecting the material to a treatment step resulting in purification of spore-form ing bacteria. Methods include administering an amount effective to engraft and/or augment in the gastrointestinal tract in order to treat or prevent a dysbiosis in the mammalian subject.

Abstract: Disclosed are methods and compositions for the prevention and treatment of food allergy. In particular, described herein are microbial consortia, including minimal microbial consortia, that can prevent and/or cure food allergy. In certain embodiments, the consortia comprise certain members of the taxa Clostridiales and/or Bacteroidetes.

Abstract: The invention relates to microbiology and medicine and can be used to prevent and treat diseases and conditions associated with disruption of normal (autochthonous) microflora (microbiota) in humans or animals. In particular, a solution for recovery or creation of the subject's microflora comprising an active component containing microorganisms isolated from the microflora of the subject or the donor, wherein the active component can be enriched with bacteriophages of said microflora and/or additional microorganisms of the microflora cultivated on a nutrient medium, while the additional microorganisms of the microflora include microorganisms of the microflora that are yet nonculturable in the absence of the host organism, is proposed.

Abstract: This invention provides an IFN inducer comprising, as an active ingredient, lactic acid bacteria and capable of inducing IFN production, an immunopotentiating agent or prophylactic agent against virus infection comprising such inducer, and a food or drink product comprising such IFN inducer and having IFN-inducing activity, immunopotentiating activity, or prophylactic activity against virus infection. The agent for inducing IFN production comprises, as active ingredients, lactic acid bacteria that can activate plasmacytoid dendritic cells (pDCs) and promote IFN production, such as Lactococcus garvieae NBRC100934, Lactococcus lactis subsp. cremoris JCM16167, Lactococcus lactis subsp. cremoris NBRC100676, Lactococcus lactis subsp. hordniae JCM1180, Lactococcus lactis subsp. hordniae JCM11040, Lactococcus lactis subsp. lactis NBRC12007, Lactococcus lactis subsp. lactis NRIC1150, Lactococcus lactis subsp. lactis JCM5805, Lactococcus lactis subsp.

Abstract: Provided herein are methods and compositions related to Bifidobacterium animalis ssp. lactis useful as therapeutic agents.

Abstract: The present invention relates to probiotic bacterial strains belonging to the genus Bifidobacterium and/or probiotic cell extracts (PCEs) thereof, having immuno stimulating, anti-inflammatory and antioxidant properties. Furthermore, the present invention relates to a composition comprising a mixture comprising or, alternatively, consisting of said probiotic bacterial strains belonging to the genus Bifidobacterium and/or probiotic cell extracts (PCEs) thereof, having immunostimulating, anti-inflammatory and antioxidant properties. Finally, the present invention relates to said composition for use in the preventive and/or curative treatment of (i) inflammatory diseases, (ii) viral, bacterial, fungal or protozoan diseases, (iii) infections, and (iv) flu, cold or fever.

Abstract: The present invention is directed to compositions comprising a mixture of microbes and the metabolites produced when the microbes are grown together. The invention is further directed to methods for making and using the compositions.

Abstract: The current invention relates to the field of a novel probiotic-curcuminoids formulation, which exhibits increased curcuminoids bioavailability, and viable probiotic microbial population in the presence of curcuminoids. The probiotic-curcuminoids formulation is made by encapsulation in ragi and galactomannan-rich fenugreek dietary fiber matrix. Compositions and methods for making this formulation are also disclosed herein.

Abstract: The present invention is related to the field of bioprotection, in particular to an antimicrobial composition comprising a Lactobacillus rhamnosus strain and/or a Lactobacillus paracasei strain. Furthermore, the present invention concerns uses for such an antimicrobial composition, food, feed and pharmaceutical products comprising such an antimicrobial composition, a method of manufacturing such food, feed and pharmaceutical products and a method for reducing the content of unwanted microorganisms of such food, feed and pharmaceutical products.

Abstract: The present invention relates to the use of probiotics, preferably one or more probiotic bacteria, to increase the absorption of proteins or the bioavailability thereof, preferably in individuals with increased protein and/or energy requirements, preferably elderly persons, children, pregnant women or athletes.

Abstract: Provided is a novel Lactobacillus acidophilus YTI strain (deposition number: KCCM 11808P); and a composition for preventing, alleviating, or treating menopause, comprising, as an active ingredient, Lactobacillus acidophilus comprising the novel strain.

Abstract: The present application generally relates to the development of live attenuated Pneumoviridae strains suitable for use as a vaccine. Particularly, human metapneumovirus (hMPV) ?M2-2 strains (rhMPV-E30M31 and rhMPV-E40L42D44) containing point mutations in a PDZ motif of M2-2, which results in a strain that is both attenuated and immunogenic and, notably, maintains the function of F and G proteins. These live attenuated hMPV strains should be suitable for use in a vaccine capable of providing protection against respiratory infection elicited by hMPV. Additionally, human respiratory syncytial virus (hRSV) strains containing point mutations in a PDZ motif of M2-2 should also be suitable for use as a vaccine capable of providing protection against respiratory infection elicited by hRSV. These Pneumoviridae strains should be useful in vaccines for use in humans and animals, e.g., companion animals and livestock, in treating or providing immunoprotection against respiratory infections.

Abstract: The present invention provide for methods of inducing an oncolytic effect on tumor cells using Zika virus. The invention also provides for inducing an oncolytic effect on brain tumors and treating brain tumors, and in particular, glioblastomas and neuroblastoma. The treatment involves the administration of Zika virus, which has an oncolytic effect on the tumor cells.

Abstract: The invention relates to therapeutic uses of gum mastic, and compounds found therein including polymeric myrcene. More particularly, the invention relates to methods of treating impaired neurological function using compositions comprising polymeric myrcene.

Abstract: The present application discloses a Chinese herbal oral paste for conditioning qi depression constitution. The Chinese herbal oral paste includes the following components: Chinese thorowax root, debark peony root, licorice, Sichuan lovage rhizome, dried tangerine peel, orange fruit, nutgrass galingale rhizome, mint, fuling, perilla leaf, largehead atractylodes rhizome, fruit of caoguo, common aucklandia root, chinaberry fruit, lychee seed, finger citron, citron fruit, rose flower, citrus aurantium L, silktree albizia bark, nardostachys root, grassleaf sweetflag rhizome, heterophylly falsestarwort root, Chinese yam, white hyacinth bean, dendrobium, turmeric root tuber, donkey-hide gelatin, turtle shell gelatin, tortoise-plastron gelatin, and xylitol.

Abstract: The present application discloses a Chinese herbal oral paste for conditioning allergic constitution. The Chinese herbal oral paste includes the following raw material components: divaricate saposhnikovia root, milkvetch root, largehead atractylodes rhizome, fructus tribuli, mulberry fruit, cicada slough, lightyellow sophora root, orange fruit, licorice, smoked plum, beautiful sweetgum fruit, glossy privet fruit, lilium brownii, cortex moutan, earthworm, villous amomum fruit, Chinese waxgourd peel, rice beans, India madder root, siegesbeckia herb, yerbadetajo herb, prepared fleeceflower root, arnebia root, tortoise-plastron gelatin, donkey-hide gelatin, and xylitol.

Abstract: The present disclosure provides a method for preparing an extract of Chrysanthemum morifolium with an effect of treating skin diseases, including: (a) performing an extraction procedure on Chrysanthemum morifolium with an extraction solvent to obtain an extract solution; and (b) adding at least one glycoside hydrolases to the extract solution to make an enzyme reaction occur to produce a precipitate, wherein the precipitate is the extract of Chrysanthemum morifolium with an effect of treating skin diseases.

Abstract: The present application discloses a Chinese herbal oral paste for conditioning phlegm-dampness constitution. The Chinese herbal oral paste includes the following raw material components: tangshen, prepared largehead atractylodes rhizome, prepared atractylodes rhizome, turmeric, unprocessed germinated barley, villous amomum fruit, coix seed, kelp, peach seed, tall gastrodia tuber, fuling, dried tangerine peel, seaweed, bitter apricot seed, cardamon fruit, perilla fruit, oriental waterplantain rhizome, ricepaperplant pith, Chinese waxgourd peel, kudzu vine root, unprocessed hawthorn fruit, milkvetch root, rice beans, lotus leaf, fortune eupatorium herb leaf, unprocessed cattail pollen, unprocessed rhubarb root and rhizome, inner membrane of chicken gizzard, white mustard seed, agastache rugosa, radish seed, xylitol, donkey-hide gelatin, and tortoise-plastron gelatin.

Abstract: The present application discloses a Chinese herbal oral paste for keeping balanced constitution. The Chinese herbal oral paste includes the following raw material components: tangshen, largehead atractylodes rhizome, fuling, prepared liquorice root, glossy privet fruit, polygonatum odoratum, dwarf lilyturf tuber, flatstem milkvetch seed, Chinese yam, unprocessed hawthorn fruit, prepared fleeceflower root, milkvetch root, dried tangerine peel, angelica, dendrobium, Chinese arborvitae kernel, root and vine of manyprickle acanthopanax, radix asparagi, danshen root, figwort root, gorgon euryale seeds, villous amomum fruit, coix seed, mulberry fruit, fruit of Chinese magnoliavine, lilium brownii, prepared milkwort root, barbary wolfberry fruit, donkey-hide gelatin, tortoise-plastron gelatin, and xylitol.

Abstract: An object of the present invention is to provide a feed for domestic animals or a supplement for domestic animals, a growth-promoting agent for a bacterium of the genus Lactobacillus, and a method for promoting growth of a bacterium of the genus Lactobacillus, by which an intestinal environment of the domestic animal can be ameliorated without externally administering bacteria, and more specifically, a proportion of bacteria of the genus Lactobacillus in intestinal bacteria can be increased. According to the present invention, there is provided a feed for domestic animals or a supplement for domestic animals, which is used for promoting growth of a bacterium of the genus Lactobacillus in the domestic animal, the feed or the supplement including at least one of a plant of the genus Salacia, an extract of the plant of the genus Salacia, or a ground product of the plant of the genus Salacia.

Abstract: The invention provides a method for extracting active therapeutic components from plant materials of the cyclanthera pedata plant which comprises immersing said plant material containing active components and selected from the group consisting of fruits, flowers, leaves, stems, twigs, bark, wood, buds, seeds, roots, and pods in a solvent for a period of time of about 30 minutes to about 10 hours to achieve transfer of active components from the plant material to the solvent, separating the solvent containing active components from the plant material, and evaporating or distilling the solvent to produce a concentrated fraction containing active components. The invention further includes compositions and therapeutic formulations of such extracts to treat hypercholesterolemia and other high lipid related diseases.

Abstract: The present invention provides a method of treating melanoma and other cancers in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of an herbal extract of PHY906 or Scutellaria baicalensis, a fraction thereof, or any active chemical present in the herbal extract or fraction thereof, and one or more immune checkpoint inhibitors. In certain embodiments, the method further comprises administering at least one herbal extract, a fraction thereof, or any active chemical present in the herbal extract or fraction thereof, of at least one herb selected from the group consisting of Glycyrrhiza uralensis, Paeonia lactiflora, and Ziziphus jujuba. The methods of the invention are useful for treating cancer such as melanoma, non-small cell lung cancer, renal cell carcinoma, liver cancer, colon cancer, urothelial bladder cancer, and/or pancreatic cancer.

Abstract: The present application discloses a Chinese herbal oral paste for conditioning blood stasis constitution. The Chinese herbal oral paste includes the following components: unprocessed rehmannia root, peony root, angelica, sichuan lovage rhizome, motherwort herb, peach seed, safflower, licorice, orange fruit, platycodon root, twotoothed achyranthes root, rose flower, cortex moutan, kudzu vine root, nutgrass galingale rhizome, unprocessed cattail pollen, Chinese cinnamon, earthworm, suberect spatholobus stem, largeleaf gentian root, milkvetch root, snakegourd root, danshen root, sanqi powder, India madder root, unprocessed hawthorn fruit, donkey-hide gelatin, turtle shell gelatin, tortoise-plastron gelatin, xylitol, and stir-baked squama manitis.

Abstract: The present application discloses a Chinese herbal oral paste for conditioning qi deficiency constitution. The Chinese herbal oral paste includes the following components: heterophylly falsestarwort root, tangshen, fuling, prepared liquorice root, root and vine of manyprickle acanthopanax6-18 parts of milkvetch root, dried tangerine peel, angelica2-8 parts of Chinese arborvitae kernel, lotus seeds, radix asparagi, danshen root, solomonseal rhizome, hyacinth bean, Chinese yam, villous amomum fruit, coix seed, glossy ganoderma, finger citron, Chinese dates, fruit of Chinese magnoliavine, lilium brownii, xylitol, and donkey-hide gelatin. The Chinese herbal oral paste of the present disclosure has a higher drug concentration and good taste, is particularly suitable for health preserving in winter and conditioning the qi deficiency constitution, will not create negative effects or harm to the human body at all, and is capable of achieving certain efficacy of strengthening physical health.

Abstract: The present application discloses a Chinese herbal oral paste for conditioning dampness-heat constitution. The Chinese herbal oral paste includes the following components: baical skullcap root, unprocessed rehmannia root, plantain seed, purslane herb, angelica, cardamon fruit, virgate wormwood herb, rice beans, weeping forsythia capsule, thunberg fritillary bulb, Chinese waxgourd peel, mint, dried tangerine peel, prepared atractylodes rhizome, waxgourd seed, common anemarrhena rhizome, amur cork-tree, golden buckwheat rhizome, fuling, Chinese yam, bitter apricot seed, coix seed, bamboo leaf, Chinese wolfberry root-bark, ural licorice root tip, common selfheal fruit-spike, white mulberry root-bark, ash bark, tortoise-plastron gelatin, turtle shell gelatin, and xylitol.

Abstract: The present application discloses a Chinese herbal oral paste for conditioning yin deficiency constitution. The Chinese herbal oral paste includes the following components: coastal glehnia root, prepared rehmannia root, dogberry, Chinese yam, cortex moutan, fuling, radix asparagi, fruit of Chinese magnoliavine, lycium barbarum, rhizoma alismatis, tremella, finger citron, fructus tribuli, ophiopogonis radix, glossy privet fruit, amomum villosum, dendrobium nobile, lilium brownii, angelica, radix paeoniae alba, licorice, radix scrophulariae, thunberg fritillary bulb, polygonatum odoratum, semen sesami nigrums, mulberry, turtle shell gelatin, tortoise-plastron gelatin, donkey-hide gelatin, xylitol, and American ginseng.

Abstract: The invention discloses odor masking formulations for stench natural compounds, selected from the extracts, fraction and pure phytochemicals that are produced in combination with a natural or synthetic hydrocolloid polymer gum(s). The invention further discloses novel process of producing the odor and taste masking formulations. The invention also discloses taste masking formulations of valerian extracts with no characteristic stench odor & or negligible stench odor in combination with natural hydrocolloid gum such as guar gum, acacia or other polymers. The invention further discloses method of reducing insomnia, anxiety, Attention Deficit Disorder (ADD), Chronic Fatigue Syndrome (CFS) using odor masking formulation of the current invention. Importantly, the said odor masked formulation of the present disclosure helps in improving sleep cycle and helps in efficient functioning of brain.

Abstract: The present application discloses a Chinese herbal oral paste for conditioning yang deficiency constitution. The Chinese herbal oral paste includes the following raw material components :prepared rehmannia root, Chinese yam,dogberry,seed of Chinese dodder, angelica, eucommia ulmoides, lycium barbarum, cinnamon, fuling, cortex moutan, rhizoma alismatis,white atractylodes rhizome, radix polygonum multiflorum preparata, dried ginseng,processed aconite root,pprepared liquorice root,cumin,herba cistanche,fruit of Chinese magnoliavine,radix cyathulae, raspberry, nutmeg, fructus broussonetiae,epimedium,fructus psoraleae,rhizoma curculiginis,rhizoma acori graminei,morinda officinalis, human placenta,cynomorium songaricum,bitter cardamon, semen allii tuberosi,antler gelatin,xylitol,walnut kernel, and donkey-hide gelatin.

Abstract: The present invention is directed to a therapeutic method of treatment of uremia associated with renal dysfunction long after transplant, comprising administering to a subject in need a therapeutically effective amount of a Chinese medicine composition. The Chinese medicine composition is the extract of the mixture including Fructus corni, radix Rehmanniae, rhizoma Dioscoreae, Radix Angelica sinensis, Cortex eucommiae, Semen cuscutae, Fructus lycii, Fructus Cinnamomum cassia, Radix aconiti lateralis preparata, Rhizoma Zingiberis, Poria, Phelloendron amurense Cortex, radix Achyranthis Bidentatae, and Atractylodes Lancea Rhizoma.

Abstract: The invention encompasses pet food compositions for a companion animal that include ginger and methods for enhancing the quality of life of an animal by administering such pet food compositions in the diet of the animal.

Abstract: In a composition and a microneedle for a localized obesity treatment containing the same in accordance with the present disclosure, the composition in accordance with the present disclosure contains a gelatin, decomposes a fat in a body, and inhibits lipogenesis and fat deposition in the body.

Abstract: The present invention relates to compositions including honey and L-alanyl-L-glutamine, pharmaceutical compositions thereof, and a combined product comprising honey and L-alanyl-L-glutamine for a simultaneous, separate, or sequential use in therapy. The composition, pharmaceutical composition, and combined product have particular utility in improving sleep and treating sleep disorders such as insomnia or sleep apnoea.